Determination of the Dissociation Constant (Ka) of Plasma and Whole Blood in Septic Patients
NCT ID: NCT03966664
Last Updated: 2019-06-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
90 participants
OBSERVATIONAL
2019-06-03
2021-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Non Carbonic Buffer Power of Critical Ill Patients With Sepsis
NCT03503214
Balanced Solution Versus Saline in Intensive Care Study
NCT02875873
Feasibility of 5% Albumin Compared With Balanced Crystalloid, as Intravenous Fluid Resuscitation in Adult Patients With Sepsis, Presenting as an Emergency to Hospital
NCT04540094
Strong Albumin Solutions in Patients With Septic Shock
NCT05208242
Experimental Determination of Atot en Ka in the Critically Ill
NCT01928745
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
A concept closely related to acid-base equilibrium is that of "buffer", term used to define any substance able to limit the changes in pH caused by the addition or loss of alkali or acid.
Depending on its physiochemical features, every buffer has one or more pH (negative logarithm of hydrogen ion concentration) values where its ability to keep pH stable is maximal. These values are defined as Ka or semi equivalence points, i.e. the pH values where the buffer dissolved in solution is half in its associated form (AH) and half in its dissociated form (A-).
Several studies tried to determine the normal values of both concentration and Ka of ATOT. However, they did not lead to univocal results. Moreover, many of these values come from studies of veterinary medicine or are the result of theoretical estimates on human plasma.
Staempfli and Constable performed a single experimental study on human plasma in 2003. These authors, however, analyzed only isolated plasma, neglecting whole blood, and computed ATOT and Ka values of healthy volunteers, while Ka and ATOT values for critically ill patients with sepsis are still unknown.
Primary aim of the present study is to quantify the acidic dissociation constant (Ka) of isolated plasma of critically ill patients with sepsis, and compare these data with normal values, i.e. obtained from healthy controls. The investigators hypothesize that plasma of critically ill septic patients has a lower Ka and that, consequently, it undergoes higher pH variations for a given perturbation of the system (variation in carbon dioxide).
Secondary aim is to quantify the Ka of whole blood of critically ill patients with sepsis and compare these data with normal values, i.e. obtained from healthy controls. The investigators hypothesize that blood of critically ill septic patients has a lower Ka and that, consequently, it undergoes higher pH variations for a given perturbation of the system (variation in carbon dioxide).
Other aims of the study are:
* quantify the Ka of plasma and whole blood of non-septic patients admitted to the ICU and compare these results with the values of septic patients and healthy volunteers.
* define the normal concentration of weak non-carbonic acids (ATOT) in plasma of septic patients and compare it with data obtained in healthy volunteers and non-septic patients.
Finally, possible structural alteration of plasma proteins will be evaluated:
* Identification of differentially modified proteoforms of serum albumin and major plasma proteins by two-dimensional electrophoresis;
* High Performance Liquid Chromatography (HPLC) to identify different Redox-forms of albumin
* Spectrophotometric evaluation of modifications of ligand binding properties of serum albumin.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Septic patients
Critically ill patients of both sexes admitted to the general ICU of the participating centers with the diagnosis of sepsis will be included.
In vitro determination the dissociation constant (Ka) and total amount of non-volatile buffers (Atot) in isolated plasma.
Collection of a venous blood sample, centrifugation in order to harvest isolated plasma and performance of in-vitro tonometry in order to assess Ka and Atot.
In vitro determination the dissociation constant (Ka) and total amount of non-volatile buffers (Atot) in whole blood
Collection of a venous blood sample and performance of in-vitro tonometry in order to assess Ka and Atot.
Biomolecular analysis of plasma proteins.
Bidimensional electrophoresis, determination of oxidized albumin fraction, characterization of altered ligand binding properties of plasma albumin.
Healthy controls
Age and sex matched healthy volunteers.
In vitro determination the dissociation constant (Ka) and total amount of non-volatile buffers (Atot) in isolated plasma.
Collection of a venous blood sample, centrifugation in order to harvest isolated plasma and performance of in-vitro tonometry in order to assess Ka and Atot.
In vitro determination the dissociation constant (Ka) and total amount of non-volatile buffers (Atot) in whole blood
Collection of a venous blood sample and performance of in-vitro tonometry in order to assess Ka and Atot.
Biomolecular analysis of plasma proteins.
Bidimensional electrophoresis, determination of oxidized albumin fraction, characterization of altered ligand binding properties of plasma albumin.
Non septic patients
Non-septic patients admitted to the general ICU of the participating centers after elective non-cardiac surgery.
In vitro determination the dissociation constant (Ka) and total amount of non-volatile buffers (Atot) in isolated plasma.
Collection of a venous blood sample, centrifugation in order to harvest isolated plasma and performance of in-vitro tonometry in order to assess Ka and Atot.
In vitro determination the dissociation constant (Ka) and total amount of non-volatile buffers (Atot) in whole blood
Collection of a venous blood sample and performance of in-vitro tonometry in order to assess Ka and Atot.
Biomolecular analysis of plasma proteins.
Bidimensional electrophoresis, determination of oxidized albumin fraction, characterization of altered ligand binding properties of plasma albumin.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
In vitro determination the dissociation constant (Ka) and total amount of non-volatile buffers (Atot) in isolated plasma.
Collection of a venous blood sample, centrifugation in order to harvest isolated plasma and performance of in-vitro tonometry in order to assess Ka and Atot.
In vitro determination the dissociation constant (Ka) and total amount of non-volatile buffers (Atot) in whole blood
Collection of a venous blood sample and performance of in-vitro tonometry in order to assess Ka and Atot.
Biomolecular analysis of plasma proteins.
Bidimensional electrophoresis, determination of oxidized albumin fraction, characterization of altered ligand binding properties of plasma albumin.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age \> 18 years
* Informed or deferred informed consent
* informed consent
* Age \> 18 years
* Informed consent
* Age \>18 years
* Planned ICU admission after elective surgery
Exclusion Criteria
* Bilirubin \> 4 mg/dL
* Minor or major thalassemia
* Transfusion of more than 4 Units of packed red blood cells and/or 1 L of plasma during the 24 hours prior to enrollment
Group 2: Healthy volunteers
• Pregnancy
Group 3: Non-septic patients
* Diagnosis of sepsis
* Pregnancy
* Bilirubin \>4 mg/dL
* Liver cirrhosis
* Onco-hematological diseases
* Minor or major thalassemia
* Transfusion of more than 4 Units of packed red blood cells and/or 1 L of plasma during the 24 hours prior to enrollment
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Charles University, Czech Republic
OTHER
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Thomas Langer, MD
Role: PRINCIPAL_INVESTIGATOR
Fondazione IRCCS Ca' Granda Hospital, Milano, Italy
Antonio M Pesenti, MD
Role: STUDY_CHAIR
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Frantisek Duska, MD
Role: PRINCIPAL_INVESTIGATOR
Third faculty of Medicine, Charles University, Prague
Giacomo Grasselli, MD
Role: STUDY_CHAIR
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Paul Elbers, MD
Role: STUDY_CHAIR
Amsterdam UMC, Department of Intensive Care Medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Third faculty of Medicine, Charles University of Prague
Prague, , Czechia
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Milan, , Italy
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Henderson LJ. THE REGULATION OF NEUTRALITY IN THE ANIMAL BODY. Science. 1913 Mar 14;37(950):389-95. doi: 10.1126/science.37.950.389. No abstract available.
Lee SW, Hong YS, Park DW, Choi SH, Moon SW, Park JS, Kim JY, Baek KJ. Lactic acidosis not hyperlactatemia as a predictor of in hospital mortality in septic emergency patients. Emerg Med J. 2008 Oct;25(10):659-65. doi: 10.1136/emj.2007.055558.
Fencl V, Leith DE. Stewart's quantitative acid-base chemistry: applications in biology and medicine. Respir Physiol. 1993 Jan;91(1):1-16. doi: 10.1016/0034-5687(93)90085-o.
LEEUWEN AM. NET CATION EQUIVALENCY ('BASE BINDING POWER') OF THE PLASMA PROTEINS. Acta Med Scand. 1964;176:SUPPL 422: 1+. No abstract available.
Figge J, Mydosh T, Fencl V. Serum proteins and acid-base equilibria: a follow-up. J Lab Clin Med. 1992 Nov;120(5):713-9.
Stampfli HR, Misiaszek S, Lumsden JH, Carlson GP, Heigenhauser GJ. Weak acid-concentration Atot and dissociation constant Ka of plasma proteins in racehorses. Equine Vet J Suppl. 1999 Jul;(30):438-42.
Staempfli HR, Constable PD. Experimental determination of net protein charge and A(tot) and K(a) of nonvolatile buffers in human plasma. J Appl Physiol (1985). 2003 Aug;95(2):620-30. doi: 10.1152/japplphysiol.00100.2003. Epub 2003 Mar 28.
Langer T, Scotti E, Carlesso E, Protti A, Zani L, Chierichetti M, Caironi P, Gattinoni L. Electrolyte shifts across the artificial lung in patients on extracorporeal membrane oxygenation: interdependence between partial pressure of carbon dioxide and strong ion difference. J Crit Care. 2015 Feb;30(1):2-6. doi: 10.1016/j.jcrc.2014.09.013. Epub 2014 Sep 22.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ENTERPRISE
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.